A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Site status not listed — check the official record
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more